Next results · Q3 2026Projected
Nov 9, after the close
Mon, Nov 9, 2026in 9 days
Projected from its last 6 releases. The company has not named the day yet.
- Quarter
- Q3 2026 · Ended Sep 30, 2026
- 10-Q window
- Nov 4 – 13
Read against Q3 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Net income
- -$12.75M
- Net income, change from a year earlier: Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m, Q3 2025 n/m
- EPS
- -$0.32
- EPS, change from a year earlier: Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m, Q2 2025 n/m
Results day
Typical moveA typical move of 6.9% either way
Up after 5 of 10, down after 5.
The stock’s move from the last close before each release to the first close after it, over the last 10 releases. Largest: +19.0% after Q4 2024.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- Usual day
- Thursday
- 4 of its last 6
- Session
- after the close
- After quarter end
- 38 to 69 days
- 10-Q filed
- 38 to 41 days
- over its last 8
- 10-K filed
- 69 to 87 days
- over its last 8
Based on 8 prior 10-Q filings.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR